Skip to main content

Table 2 Clinical trials of immune checkpoint blockade in EC

From: The immune landscape of esophageal cancer

Target Drug Treatment Phase Study ID Outcome summary
PD-1 Pembrolizumab Pembrolizumab alone IB Keynote-028 ORR 30% in PD-L1+ EC
Pembrolizumab alone II Keynote-180 (NCT02559687) ORR 14.3% in ESCC and 5.2% in EAC
Pembrolizumab vs. irinotecan or taxanes III Keynote-181 (NCT02564263) Median OS in ESCCs: 8.2 vs. 7.1 months
ORR in ESCCs: 16.7% vs. 7.4%
Pembrolizumab + cisplatin and 5-fluorouracil vs. placebo III Keynote-590 (NCT03189719) Ongoing
PD-1 Nivolumab Nivolumab vs. taxanes III NCT02569242 Median OS in ESCCs: 10.9 vs. 8.4 months
Nivolumab alone II JapicCTI-142422 17% of ESCC patients had a centrally assessed objective response
Nivolumab vs. placebo III Checkmate-577 (NCT02743494) Ongoing
Nivolumab + ipilimumab or nivolumab + fluorouracil + cisplatin vs. fluorouracil + cisplatin III Checkmate-648 (NCT03143153) Ongoing
  SHR-1210 SHR-1210 alone I NCT0274293 ORR 30% and median PFS 3.6 months in ESCC
SHR-1210 vs. docetaxel or irinotecan III NCT03099382 N/A
CTLA-4 Ipilimumab N/A I NCT01738139 Ongoing
PD-1/CTLA-4 Nivolumab/ipilimumab Nivolumab (3 mg/kg) vs. nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) vs. nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) I/II CheckMate-032 ORR in patients with gastric, esophageal, or gastroesophageal junction cancer: 12% vs. 24% vs. 8%
  1. N/A not available, ORR objective response rate, EC esophageal cancer, ESCC esophageal squamous cell carcinoma, EAC esophageal adenocarcinoma, OS overall survival, PFS progression-free survival, PD-1 programmed death protein-1, CTLA-4 cytotoxic T lymphocyte-associated protein 4